Evaluating the Use of Nonrandomized Real‐World Data Analyses for Regulatory Decision Making
暂无分享,去创建一个
David Martin | Sebastian Schneeweiss | Jessica M Franklin | Robert J Glynn | S. Schneeweiss | R. Glynn | J. Franklin | David Martin
[1] L. Howie,et al. A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics: A Review , 2018, JAMA oncology.
[2] Marsha E Reichman,et al. Dabigatran and postmarketing reports of bleeding. , 2013, The New England journal of medicine.
[3] James R. Rogers,et al. Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi‐Database Cohort Study , 2017, Arthritis & rheumatology.
[4] James M. Robins,et al. Observational Studies Analyzed Like Randomized Experiments: An Application to Postmenopausal Hormone Therapy and Coronary Heart Disease , 2008, Epidemiology.
[5] R Platt,et al. Real World Data in Adaptive Biomedical Innovation: A Framework for Generating Evidence Fit for Decision‐Making , 2016, Clinical pharmacology and therapeutics.
[6] Samy Suissa,et al. Immortal time bias in observational studies of drug effects , 2007, Pharmacoepidemiology and drug safety.
[7] S. Schneeweiss,et al. Claims‐based studies of oral glucose‐lowering medications can achieve balance in critical clinical variables only observed in electronic health records , 2018, Diabetes, obesity & metabolism.
[8] A. Avogaro,et al. Analyses of Results From Cardiovascular Safety Trials With DPP-4 Inhibitors: Cardiovascular Outcomes, Predefined Safety Outcomes, and Pooled Analysis and Meta-analysis , 2016, Diabetes Care.
[9] R. Guthrie. Canagliflozin and cardiovascular and renal events in type 2 diabetes , 2018, Postgraduate medicine.
[10] John P. A. Ioannidis,et al. What does research reproducibility mean? , 2016, Science Translational Medicine.
[11] D. Karnad,et al. The Genesis of Cardiovascular Safety Regulatory Landscapes for New Antidiabetic Drugs for Type 2 Diabetes , 2017 .
[12] Jeremy A. Rassen,et al. Transparency and reproducibility of published observational cohort studies , 2015 .
[13] S. Pocock,et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2007, Preventive medicine.
[14] S. Yusuf,et al. Dual inhibition of the renin–angiotensin system in high-risk diabetes and risk for stroke and other outcomes: results of the ONTARGET trial , 2013, Journal of hypertension.
[15] Sebastian Schneeweiss,et al. When and How Can Real World Data Analyses Substitute for Randomized Controlled Trials? , 2017, Clinical pharmacology and therapeutics.
[16] R. Simon,et al. The role of nonrandomized trials in the evaluation of oncology drugs , 2015, Clinical pharmacology and therapeutics.
[17] Danielle E. Clarkesmith,et al. Cochrane Database of Systematic Reviews Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation (Review) , 2017 .
[18] Robert C. Wolpert,et al. A Review of the , 1985 .
[19] Sebastian Schneeweiss,et al. Use of Health Care Databases to Support Supplemental Indications of Approved Medications , 2018, JAMA internal medicine.
[20] Suzanne Bonamici. Text - H.R.34 - 114th Congress (2015-2016): 21st Century Cures Act , 2016 .
[21] S. Cole,et al. Overadjustment Bias and Unnecessary Adjustment in Epidemiologic Studies , 2009, Epidemiology.
[22] D. Solomon,et al. Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol: Population-Based Cohort Study , 2018, Circulation.
[23] J. Gagne,et al. Safety assessment of niacin in the US Food and Drug Administration's mini‐sentinel system , 2018, Pharmacoepidemiology and drug safety.
[24] F. J. Sasinowski,et al. Quantum of Effectiveness Evidence in FDA’s Approval of Orphan Drugs , 2012 .
[25] Samy Suissa,et al. Immortal time bias in pharmaco-epidemiology. , 2008, American journal of epidemiology.
[26] J. Avorn,et al. Paradoxical Relations of Drug Treatment with Mortality in Older Persons , 2001, Epidemiology.
[27] J M Rowe,et al. Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia , 2016, Blood Cancer Journal.
[28] S. Pocock,et al. Guidelines for Reporting Observational Studies , 2007 .
[29] Chittaranjan Andrade,et al. Confounding , 2007, Indian journal of psychiatry.
[30] John D Seeger,et al. Aprotinin during coronary-artery bypass grafting and risk of death. , 2008, The New England journal of medicine.
[31] S. Yusuf,et al. Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[32] R. Martineau,et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. , 2008, The New England journal of medicine.
[33] J. Rassen,et al. Prospective Cohort Studies of Newly Marketed Medications: Using Covariate Data to Inform the Design of Large-Scale Studies , 2014, Epidemiology.
[34] S. Schneeweiss. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics , 2006, Pharmacoepidemiology and drug safety.
[35] K. Huybrechts,et al. Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation , 2015, Thrombosis and Haemostasis.
[36] Guidance for Industry E 10 Choice of Control Group and Related Issues in Clinical Trials , 2001 .
[37] Kenneth G Saag,et al. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout , 2018, The New England journal of medicine.
[38] T C Chalmers,et al. Randomized versus historical controls for clinical trials. , 1982, The American journal of medicine.
[39] Lisa M. LaVange,et al. Multidimensional Evidence Generation and FDA Regulatory Decision Making: Defining and Using "Real-World" Data. , 2017, JAMA.
[40] George Davey Smith,et al. Negative control exposures in epidemiologic studies. , 2012, Epidemiology.
[41] R. Califf,et al. Real-World Evidence - What Is It and What Can It Tell Us? , 2016, The New England journal of medicine.
[42] JA Rassen,et al. Transparency and Reproducibility of Observational Cohort Studies Using Large Healthcare Databases. , 2016, Clinical pharmacology and therapeutics.
[43] H. Eichler,et al. Adaptive Licensing: Taking the Next Step in the Evolution of Drug Approval , 2012, Clinical pharmacology and therapeutics.
[44] J. Ioannidis. Why Most Published Research Findings Are False , 2005, PLoS medicine.
[45] W Goettsch,et al. From adaptive licensing to adaptive pathways: Delivering a flexible life‐span approach to bring new drugs to patients , 2015, Clinical pharmacology and therapeutics.
[46] Jeremy Sugarman,et al. Ethics and regulatory complexities for pragmatic clinical trials. , 2014, JAMA.
[47] Duke-Margolis. Characterizing RWD Quality and Relevancy for Regulatory Purposes , 2018 .
[48] L. Bero,et al. Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials. , 2014, The Cochrane database of systematic reviews.
[49] W Katherine Yih,et al. Intussusception risk after rotavirus vaccination in U.S. infants. , 2014, The New England journal of medicine.
[50] Laura McDonald,et al. Real-world data in the United Kingdom: opportunities and challenges , 2016, BMC Medicine.
[51] D. Karnad,et al. Cardiovascular Safety in Drug Development and Therapeutic Use , 2017, Springer International Publishing.
[52] C Michael Stein,et al. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease , 2002, The Lancet.
[53] Douglas G Altman,et al. [The Strengthening the Reporting of Observational Studies in Epidemiology [STROBE] statement: guidelines for reporting observational studies]. , 2007, Gaceta sanitaria.
[54] W. Klapper,et al. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia , 2017, The New England journal of medicine.
[55] J. Avorn,et al. A review of uses of health care utilization databases for epidemiologic research on therapeutics. , 2005, Journal of clinical epidemiology.
[56] A. Alavi,et al. Opportunities and Challenges , 1998, In Vitro Diagnostic Industry in China.
[57] R. J. Hayes,et al. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. , 1995, JAMA.
[58] F. Dominici,et al. Reproducible epidemiologic research. , 2006, American journal of epidemiology.
[59] S S Ellenberg,et al. Placebo-Controlled Trials and Active-Control Trials in the Evaluation of New Treatments. Part 1: Ethical and Scientific Issues , 2000, Annals of Internal Medicine.
[60] S. Schneeweiss,et al. Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study , 2018, British Medical Journal.
[61] Sebastian Schneeweiss,et al. Selective prescribing led to overestimation of the benefits of lipid-lowering drugs. , 2006, Journal of clinical epidemiology.
[62] M. Lipsitch,et al. Negative Controls: A Tool for Detecting Confounding and Bias in Observational Studies , 2010, Epidemiology.